share_log

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

Benzinga Real-time News ·  Mar 30, 2022 08:04

Here's a roundup of top developments in the biotech space over the last 24 hours.

Stocks In Focus

J&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents

Johnson & Johnson's(NYSE:JNJ) Janssen unit said the U.S. Food and Drug Administration has approved Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents, who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.

Cabenuva has been...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment